DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* GENFIT *


 

1999 - North-Picardie
Lille
www.genfit.com

 

Discovery, Drugs
Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes
Mission: to bring therapeutic and diagnostic solutions to combat the major health concerns of diabetes, its associated risk factors, and its complications
Clients: Pharmaceutical industry
contact@genfit.com

Age: 17 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M, also chairman]
Oper.Dir.-COO: Darteil (Raphaël) [Ph.D. molecular and cellular biology, ex-Aventis]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem]
BusDev:
Financers (Hist.): Finorpa, Nord Cration, BP Création, Ya Global, University Lille II, Public

Turnover (M€) : 5.9 (2009), 8.8 (2008), 9.9 (2006)
Total funding (M€) : n.a.
Last funding (M€) : 14.0
Focus : Cardiovasc
Position : Clinical
Company confirm : 6-May-2011

 

History
DATEMILESTONETYPETIME
2013 .04 Financing (new shares) : 14.0 M€ in private placement, to enhance development programs (GFT505, in phase IIb, TGFTX1 and TGFTX3) RFIN [13 years]
2012 .10 Financing (new shares) : 2.0 M€ in convertible bonds, all being converted into new shares by YA Global Master, one of the historical shareholders RFIN [13 years]
2012 .05 Clinical trial (phase IIa) in GFT505 with a dose three-fold higher in obese subjects (followed by the beginning of an FDA phase IIb study in September) CLIN [12 years]
2012 .04 Financing (new shares) : 0.6 M€, by YA Global Master, as a private placement reserved to one of the historical shareholders (also 0.5 M€ in July to an undisclosed historical shareholder) RFIN [12 years]
2011 .11 Financing (new shares) : 0.5 M€, by University Lille II (France), as a private placement reserved to one of the historical shareholders RFIN [12 years]
2011 .08 Financing (new shares) : 5.3 M€, by YA Global Master (Yorkville Advisors) and 5.1 M€ by existing shareholders, for GFT505 further development (increased by 0.1 M€ in November, again with Yorkville) RFIN [11 years]
2011 .07 Clinical trial (phase IIa) in NAFLD/NASH and the prevention of cardiovascular risk in diabetic patients (completed, positive) CLIN [11 years]
2011 .03 Partnering research agreement with Sanofi-Aventis for new drugs for the treatment of metabolic disorders (undisclosed annual payments and milestone payments up to 39 M€ according to R&D progress) R&D [11 years]
2010 .12 Financing (funding) : 1.2 M€ (as part of the EuroTransBio funding initiative), for the OLNORME (Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites) program RFIN [11 years]
2010 .09 Clinical trial (phase I) for GFT505 on healthy volunteers showing it potentiates insulin action in humans (end), followed by the beginning of a phase II CLIN [11 years]
2010 .07 Financing (no interest loan) : 2.3 M€, by OSEO, for early development DEBT [10 years]
2010 .02 Financing (capital increase) : 2.3 M€ on Alternext PBO [10 years]
2009 .11 Clinical trial (phase II) for GFT505 (end) in prediabetic patients with atherogenic dyslipidemia and abdominal obesity CLIN [10 years]
2009 .03 Licensing-in by acquisition of the research program MKG02 focused on type 2 diabetes and obesity, from Merck Serono LICIN [9 years]
2009 .02 Research : new theranostic strategy unveiled with an innovative biomarker technology dedicated to early detection of atherosclerosis R&D [9 years]
2008 .06 Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genoway, SpiBio, Roowin and Academic Institutions, over 5 years DEBT [8 years]
2008 .04 Management crisis : direct conflict between 2 co-founders, Jean-François Mouney, CEO and Jean-Charles Fruchart, President of Supervisory Board (dismissed) ORG [8 years]
2006 .12 Listing on Alternext : 15.0 M€ PBO [7 years]
2006 .05 Clinical trial (phase II) for first lead, GFT14 (beginning) CLIN [6 years]
2003 .00 Set-up of international offices in Cambridge (USA) ORGC [3 years]
2000 .03 Seed financing : 2 M€, by UCB, Aventis, Sanofi-Synthelabo, Merck-Lipha, Finorpa, Nord Création, BP Création SFIN [0 year]
1999 .09 Company founded by Prof. Jean-Charles Fruchart (born 1945), Jean-François Mouney, Prof. Bart Staels, Florence Séjourné ORGF [0 year]

Actualisation / Updating: 19-Apr-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende